Amlodipine-based regimen reduces cardiovascular events better than standard tretament


The results of a randomised trial, published in The Lancet, demonstrated that a combination of modern anti-hypertensive drugs can reduce a patient’s risk of stroke and heart attack to a greater extent than standard treatments.

Hypertension is the most important preventable cause of premature death in developed countries, and the benefits of antihypertensive drugs for prevention of cardiovascular mortality and morbidity are well established.
However, no individual trial using standard diuretic or beta-blocker therapy, or both has shown a significant reduction in coronary heart disease.
Previous studies have suggested that newer agents would confer advantages over diuretics and beta-blockers.

In the Anglo-Scandinavian Cardiac Outcomes Trial ( ASCOT ), Bjorn Dahlof , from Sahlgrenska University Hospital, Sweden, and colleagues compared the effect of combinations of older drugs - Atenolol ( Ternomin ) and Thiazide - with newer drugs, Amlodipine ( Norvasc ) and Perindopril ( Aceon ).

The investigators recruited 19257 patients aged between 40–79 years who had a least three other risk factors for cardiovascular events. Half of the patients were assigned the Atenolol-based regimen and half the Amlodipine-based regimen.

After 5 years the investigators found those allocated the Amlodipine-based regimen had lower blood pressure values than those on the Atenolol-based regimen.
They also found that the newer drugs prevented more major cardiovascular events and caused fewer cases of diabetes than the older drugs.

Dahlof comments: “ The preferential reduction in cardiovascular events associated with an antihypertensive regimen of a calcium-channel blocker, Amlodipine, with addition of Perindopril if necessary, particularly when used in combination with effective lipid lowering, results in the prevention of most major cardiovascular events associated with hypertension. We hope these results will be used to inform clinical practice in ways that should greatly reduce the burden of cardiovascular disease to which patients with hypertension are exposed.”

Source: The Lancet, 2005


XagenaMedicine_2005



Indietro

Altri articoli

Conflicting blood pressure-lowering effects of catheter-based renal artery denervation have been reported in patients with resistant hypertension. Researchers have compared...


Hypertension is a common diabetes comorbidity that affects the majority of patients, with the prevalence depending on type of diabetes,...


Calcium channel blockers are a heterogeneous class of drugs, including dihydropyridine and non-dihydropyridine subgroups, commonly used in the treatment of...


In previous clinical trials in high-risk hypertensive patients, paradoxically higher cardiovascular event rates have been reported in patients of normal...


Tribenzor is a combination of Amlodipine, Hydrochlorothiazide, and Olmesartan medoxomil. Amlodipine is a calcium channel blocker. Amlodipine is a peripheral...


The FDA ( Food and Drug Administration ) has approved Tribenzor ( Olmesartan medoxomil, Amlodipine, Hydrochlorothiazide ), a new three-in-one...


New research by The University of Texas School of Public Health has shown that a diuretic is particularly effective at...


The "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial " or ALLHAT shows that in people with diabetes,...


Thiazide-type diuretics remain the drugs of choice for initial therapy of high blood pressure in both black and non-black patients. ...


According to the VAST study, patients with moderate to severe hypertension treated with a combination of Diovan ( Valsartan; Tareg...